WHO SMART Guidelines - Measles Immunization
0.1.0 - ci-build
WHO SMART Guidelines - Measles Immunization, published by WHO. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/WorldHealthOrganization/smart-example-immz/ and changes regularly. See the Directory of published versions
| Official URL: http://smart.who.int/immunizations-measles/PlanDefinition/IMMZD2DTMeaslesDose0 | Version: 0.1.0 | |||
| Draft as of 2024-09-21 | Computable Name: IMMZD2DTMeaslesDose0 | |||
If the child or patient has not been given MCV0 between 6 and 9 months
Generated Narrative: PlanDefinition IMMZD2DTMeaslesDose0
CQF Knowledge capability: computable
url: PlanDefinition IMMZ.D2.DT.Measles MCV Dose 0
version: 0.1.0
name: IMMZD2DTMeaslesDose0
title: IMMZ.D2.DT.Measles MCV Dose 0
type: ECA Rule
status: Draft
experimental: true
date: 2024-09-21 14:59:40+0000
publisher: WHO
contact: WHO: http://who.int
description:
If the child or patient has not been given MCV0 between 6 and 9 months
| Type | Citation |
| Citation | WHO recommendations for routine immunization - summary tables (March 2023) |
library: IMMZD2DTMeaslesDose0Logic
action
CPG Rationale Extension:
Note: The countries should apply the national immunization policy for MCV0 dose and adjust this logic accordingly.<br/>A supplementary dose of MCV (recorded as MCV0) should be considered for infants known to be exposed (i.e. born to an HIV-infected woman) or soon after diagnosis of HIV infection in children older than 6 months who are not receiving HAART and for whom the risk of measles is high, with the aim of providing partial protection until they are revaccinated after immune reconstitution with HAART.<br/>In the following situations, a supplementary dose of MCV should be given to infants from 6 months of age:<br/>* (1) during a measles outbreak as part of intensified service delivery;<br/>* (2) during campaigns in settings where the risk of measles among infants < 9 months of age remains high (e.g. in endemic countries experiencing regular outbreaks);<br/>* (3) for internally displaced populations and refugees, and populations in conflict zones;<br/>* (4) for individual infants at high risk of contracting measles (e.g. contacts of known measles cases or in settings with increased risk of exposure during outbreaks such as day-care facilities);<br/>* (5)for infants travelling to countries experiencing measles outbreaks;<br/>* (6) infants known to be HIV-infected or exposed (i.e. born to an HIV-infected woman).<br/>In areas where there is a high incidence of both HIV infection and measles, an initial dose of MCV may be offered as early as age 6 months (recorded as MCV0). The 2 routine doses of MCV (MCV1 and MCV2) should then be administered to these children according to the national immunization schedule.<br/>As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine.
title: Immunize patient for Measles
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier Measles Routine Immunization Schedule Incomplete action
action